RxDoctor Payments Data

Sara Rhoten

Nurse Practitioner · Cincinnati, OHNPI 1831637362

Payments from drug & device makers

$3,750in general payments, 2019–2025

Across 101 payments — averaging $37.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vifor Pharma, Inc.$546
  • Mallinckrodt Hospital Products Inc.$508
  • Bayer$411
  • Calliditas Therapeutics US Inc.$322
  • Apellis Pharmaceuticals, Inc.$292
  • Veloxis Pharmaceuticals, Inc.$264
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$3,67398%
  • Education$782%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,750 in reported general payments places this provider in the 95th percentile of 4,700 nurse practitioner providers in Ohio.

See all nurse practitioner providers in Ohio

Medicare billing

Part B allowed, 2024
$42,015
Medicare patients
175
Services billed
396

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AuryxiaFerric Citrate22$30,177
Sevelamer Carbonate91$15,041
EliquisApixaban15$12,579
LokelmaSodium Zirconium Cyclosilicate23$8,535
ProsolParenteral Amino Acid 20% No.134$4,264
Nifedipine ErNifedipine93$2,545
Midodrine Hcl72$2,470
Calcium Acetate36$1,780
Metoprolol Succinate36$505
Torsemide30$443
Tamsulosin Hcl21$353
Pantoprazole Sodium21$246
Losartan Potassium26$236
Doxazosin Mesylate15$224
Cinacalcet Hcl11$199

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Akebia Therapeutics IncAuryxia$200$30,17722 claims
AstraZenecaLokelma$212$8,53523 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,700 nurse practitioner providers in Ohio.

Other nurse practitioner in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →